KR101713119B1 - Manufacturing method of salmon deoxyribonucleic acid film and apparatus for injecting medicine using the salmon deoxyribonucleic acid film - Google Patents

Abstract

The present invention relates to a method for producing a salmon nucleic acid film, and to a medicine injecting device using the salmon nucleic acid film. The salmon nucleic acid film can prevent skin troubles and improve skin penetration of a medicine by being applied to a transdermal delivery scheme depending on the diffusion of a medicine across skin. To this end, the method comprises: a mixing step of producing a mixed liquid by feeding 0.5 to 5 parts by weight of salmon nucleic acid in a powder type to 100 parts by weight of distilled water or deionized water; an agitating step of agitating the mixed liquid from the mixing step; a mixed liquid coating step of coating the mixed liquid on a mold corresponding to the shape of a completed salmon nucleic acid film; and a drying step of drying the mixed liquid coated on the mold to change the mixed liquid coated on the mold into a salmon nucleic acid film.

Description

TECHNICAL FIELD [0001] The present invention relates to a method for producing a salmon nucleic acid film and a drug injection device using the salmon nucleic acid film. ≪ Desc / Clms Page number 1 >

The present invention relates to a method for producing a salmon nucleic acid film and a drug injection device using the salmon nucleic acid film. More particularly, the present invention relates to a drug delivery device using a salmon nucleic acid film in transdermal delivery technology, And a drug infusion device using the salmon nucleic acid film. The present invention also relates to a drug injection device using the salmon nucleic acid film.

In general, most drugs are administered orally. However, some drugs, particularly protein and peptide drugs, can not be effectively adsorbed in this manner due to severe degradation in the gastrointestinal tract, poor absorption in the intestinal membranes, and / or interruption of first pass by the liver.

Other drug delivery techniques are parenteral injection using standard syringes or catheters. Syringe injection causes needle phobia, substantial pain, and local damage to the skin in many patients. Recovery of body fluids such as blood for diagnostic purposes causes similar anxiety. In addition, needle injection is not ideal for continuous delivery of the drug, or for continuous diagnosis.

Another drug delivery technique is transdermal delivery, which is usually dependent on the diffusion of the drug across the skin. This method is not widely applied due to the insufficient skin permeability of many drugs. The outermost layer of the skin, the stratum corneum, represents the main barrier against transdermal drug penetration. Once the drug reaches the dermis depth (below the epidermis), the drug rapidly spreads through the blood circulation into the deep tissue layer and other parts of the body.

In an attempt to improve protein drug delivery rate through the skin, chemical enhancers, iontophoresis, electroporation, ultrasound, and thermal elements have been used to supplement drug delivery. However, these techniques are not suitable for some drug forms and often do not provide a therapeutic level of delivery. These techniques sometimes cause unwanted skin reactions and are impractical for the control of drug delivery in delivering the drug over a period of hours or days.

Korean Patent Laid-Open Publication No. 2008-0050580 (title of the invention: solid solution perforator containing drug particles and / or drug adsorbed particles, published on June 06, 2008)

SUMMARY OF THE INVENTION It is an object of the present invention to solve the problems of the prior art by applying a salmon nucleic acid film in a transdermal delivery technique which depends on drug diffusion across the skin to prevent skin troubles and improve skin penetration of drugs A method for producing a salmon nucleic acid film, and a drug injection device using a salmon nucleic acid film.

According to a preferred embodiment of the present invention, the method for producing a salmon nucleic acid film according to the present invention comprises the steps of: putting 0.5 to 5 parts by weight of salmon nucleic acid into 100 parts by weight of distilled water or deionized water in powder form A mixing step of forming a mixed liquid; Stirring the mixed liquid through the mixing step; Applying the mixed solution to a molding mold corresponding to the shape of the finished salmon nucleic acid film; And drying the mixed liquid applied to the molding die so that the mixed liquid applied to the molding die is converted into the salmon nucleic acid film.

The method for producing a salmon nucleic acid film according to the present invention further includes a surface treatment step of treating the surface of the molding mold with a hydrophobic property prior to the step of applying the mixed solution.

The method for producing a salmon nucleic acid film according to the present invention further includes a film obtaining step of separating the salmon nucleic acid film from the molding mold through the drying step.

In the mixing step, 1 to 100 parts by weight of the drug is further added to the mixed solution in the form of a liquid, a powder or a capsule.

The drug injection device using the salmon nucleic acid film according to the present invention is a salmon nucleic acid film manufactured according to the above-described manufacturing method to be in contact with the skin of a human body; A finish film laminated and supported on the salmon nucleic acid film; And a drug filled between the salmon nucleic acid film and the finish film.

The drug injection device using the salmon nucleic acid film according to the present invention is a salmon nucleic acid film manufactured according to the above-described manufacturing method to be in contact with the skin of a human body; A boundary film laminated and supported on the salmon nucleic acid film; A finishing film laminated and supported on the boundary film, the finishing film having a perforation needle protruding from the boundary film; A drug filled between the salmon nucleic acid film and the boundary film; And a decomposition liquid filled between the boundary film and the finishing film, the decomposition liquid being composed of distilled water or deionized water.

The drug injection device using the salmon nucleic acid film according to the present invention comprises a salmon nucleic acid film prepared by mixing salmon nucleic acid and drug in distilled water or deionized water so as to be in contact with the skin of a human body.

The drug infusion device using the salmon nucleic acid film according to the present invention comprises: a boundary film laminated and supported on the salmon nucleic acid film; A finishing film laminated and supported on the boundary film, the finishing film having a perforation needle protruding from the boundary film; And a decomposition liquid filled between the boundary film and the finish film, the decomposition liquid being composed of distilled water or deionized water.

Here, in the salmon nucleic acid film, a microneedle is extended so as to face the skin of the human body.

Here, in the salmon nucleic acid film, a buffer groove in which the drug is contained is recessed.

The drug delivery hole extends through the salmon nucleic acid film so as to extend toward the skin of the human body. The drug delivery hole is formed through the drug delivery hole such that the drug is discharged at a force greater than the surface tension of the drug.

The drug injection device using the salmon nucleic acid film according to the present invention further includes a protective film detachably coupled to the salmon nucleic acid film so that the drug injection hole is opened and closed.

According to the method for manufacturing a salmon nucleic acid film and the drug injection device using a salmon nucleic acid film according to the present invention, it is possible to prevent skin troubles by applying a salmon nucleic acid film in a transdermal delivery technique that depends on drug diffusion across the skin, The skin permeability of the drug can be improved.

In addition, the present invention can easily form a drug delivery portion having a microneedle, a buffer groove, and a drug injection hole penetrating through the salmon nucleic acid film, and the thickness of the salmon nucleic acid film can be uniformly formed.

Further, the present invention can prevent foreign matter from mixing with the salmon nucleic acid film and improve the degree of decomposition of the salmon nucleic acid film.

Further, the present invention can stably supply the degradation solution to the salmon nucleic acid film and stabilize the supply of the drug.

In addition, the present invention can form a pattern according to the dosage form of the drug, and can control the dose of the drug according to the pattern.

In addition, the present invention can prevent the drug from leaking from the drug infusion hole, prevent foreign substances from entering the drug, and protect the salmon nucleic acid film.

1 is a flowchart showing a method of manufacturing a salmon nucleic acid film according to an embodiment of the present invention.
FIG. 2 is a view showing a process state according to a method of manufacturing a salmon nucleic acid film according to an embodiment of the present invention.
3 is a cross-sectional view illustrating a molding die used in a method of manufacturing a salmon nucleic acid film according to an embodiment of the present invention.
FIG. 4 is a photograph showing a micro needle provided in a salmon nucleic acid film according to an embodiment of the present invention.
FIG. 5 is a cross-sectional view illustrating a drug injection device using a salmon nucleic acid film according to a first embodiment of the present invention.
6 is a cross-sectional view illustrating a drug injection device using a salmon nucleic acid film according to a second embodiment of the present invention.
7 is a cross-sectional view illustrating a drug injection device using a salmon nucleic acid film according to a third embodiment of the present invention.
FIG. 8 is a cross-sectional view illustrating a drug injection device using a salmon nucleic acid film according to a fourth embodiment of the present invention.

Hereinafter, a method for producing a salmon nucleic acid film according to the present invention and an apparatus for injecting a drug using salmon nucleic acid film will be described with reference to the accompanying drawings. Here, the present invention is not limited or limited by the examples. Further, in describing the present invention, a detailed description of well-known functions or constructions may be omitted for clarity of the present invention.

FIG. 1 is a flow chart showing a method of manufacturing a salmon nucleic acid film according to an embodiment of the present invention, FIG. 2 is a view showing a process state according to a method of manufacturing a salmon nucleic acid film according to an embodiment of the present invention, FIG. 3 is a cross-sectional view illustrating a molding die used in a method of manufacturing a salmon nucleic acid film according to an embodiment of the present invention, and FIG. 4 is a cross-sectional view illustrating a microneedle provided in a salmon nucleic acid film according to an embodiment of the present invention It is a photograph.

1 to 4, a method for producing a salmon nucleic acid film according to an embodiment of the present invention is a method for producing a salmon nucleic acid film 10 using a powdery salmon nucleic acid 1b, (S1), a stirring step (S2), a mixed liquid applying step (S3) and a drying step (S4), and further includes at least one of a surface treatment step (S5) and a film obtaining step .

In the mixing step (S1), the salmon nucleic acid (1b) is added to the aqueous solution (1a) in the mixing container (1) to form a mixed solution. The mixing vessel 1 has a narrower width toward the bottom, so that the aqueous solution 1a and the salmon nucleic acid 1b can be stably stirred. At this time, the aqueous solution (1a) is composed of distilled water or deionized water, and the salmon nucleic acid (1b) is in a powder form. Then, 0.5 to 5 parts by weight of the salmon nucleic acid (1b) is added to 100 parts by weight of the aqueous solution (1a, distilled water or deionized water) to form a mixed solution. The amount of the salmon nucleic acid 1b may be adjusted depending on the thickness of the finished salmon nucleic acid film 10.

For example, the amount of the salmon nucleic acid 1b may be 0.5 to 2 parts by weight. The amount of the salmon nucleic acid (1b) may be 1 part by weight to 3 parts by weight. The amount of the salmon nucleic acid (1b) may be 0.5 part by weight to 3 parts by weight. In other words, the input amount of the salmon nucleic acid (1b) can be changed between 0.5 and 5 parts by weight and 0.5 part by weight.

When the amount of the salmon nucleic acid 1b is out of the range of the amount of the salmon nucleic acid 1b, cracks may be generated in the finally completed salmon nucleic acid film 10 because holes or protrusions are not formed in the finished salmon nucleic acid film 10 have. However, if the input amount of the salmon nucleic acid 1b falls within the above-described numerical limit range, the finally completed salmon nucleic acid film 10 exhibits a stable film shape and cracks are generated in the finally completed salmon nucleic acid film 10 And the salmon nucleic acid film 10 which is finally completed within a predetermined time can be easily decomposed by the decomposition liquid 50 described later.

The mixing vessel 1 is washed with deionized water, isopropyl alcohol, acetone and deionized water in that order, and then the aqueous solution (1a) and the salmon nucleic acid (1b) Contamination of the salmon nucleic acid 1b can be prevented.

Particularly, in the mixing step (S1), 1 part by weight to 100 parts by weight of the drug (40) may be further added in the form of a liquid, a powder or a capsule. In other words, the dosage of the drug 40 can be changed between 1 part by weight and 100 parts by weight and 0.5 part by weight. The dose of the drug 40 can be adjusted depending on the amount of the penetration of the human skin.

Then, the salmon nucleic acid 1b and the drug 40 are mixed in the aqueous solution 1a, and the salmon nucleic acid 1b and the drug 40 are integrated with each other in the finally completed salmon nucleic acid film 10 .

The stirring step (S2) stirs the mixed liquid through the mixing step (S1). In the stirring step S2, the inlet of the mixing vessel 1 is sealed with a sealing material 4 such as parafilm or the like, and the mixture is stirred in the stirring unit 2. For example, as the stirring unit 2 uses the magnetic stirrer, the mixing container 1 can be immersed in the magnet 3 cleaned with deionized water. At this time, the magnet (3) can be sealed by the bar stiffener (4). In the stirring step S2, the mixed solution is rotated only in one direction to maintain the cone shape so that the salmon nucleic acid 1b is uniformly mixed in the mixed solution.

The stirring step (S2) is performed for 10 hours to 24 hours at a rotational speed of 600 rpm to 1000 rpm. For example, the stirring step (S2) may be carried out at a rotational speed of 700 rpm for 1 hour to 1.5 hours and further stirred at a rotational speed of 900 rpm for 9 hours to 10 hours. In the stirring step S2, the mixed state of the mixed liquid can be stabilized by leaving the remaining time in the space where ultraviolet rays and sunlight are blocked.

In the mixed liquid applying step (S3), the mixed liquid which has been stirred through the stirring step (S2) is applied to the molding die (5). The shaping mold 5 may show the necessary shape corresponding to the shape of the finished salmon nucleic acid film 10.

The amount of the mixed solution applied to the molding die 5 may be adjusted according to the size and thickness of the finished salmon nucleic acid film 10.

In the mixed liquid applying step (S3), the mixed liquid is applied to the forming mold (5) and vacuumed for about 1 hour (55 to 70 minutes) to apply the mixed liquid in the forming mold Thereby stabilizing the state and promoting the drying of the mixed liquid.

In the drying step S4, the mixed liquid applied to the molding die 5 is dried so that the mixed liquid applied to the molding die 5 is converted into the salmon nucleic acid film 10. In the drying step (S4), the molding die (5) coated with the mixed liquid is dried in the drying unit (7) at a predetermined temperature for a predetermined time. The drying step (S4) may be performed for 2 to 4 days in the drying unit (7) maintaining the temperature of 40 to 60 degrees Celsius. For example, the drying step S4 may be performed for 3 days to 4 days in the drying unit 7 maintaining the temperature of 45 ° C to 50 ° C. If the temperature of the drying step S4 is lower than the critical temperature and the time required for drying is increased and the temperature of the drying step S4 is higher than the critical temperature, A cause of defects such as cracks may occur. Accordingly, the salmon nucleic acid film 10 can be completed as the temperature of the drying step S4 is dried for a certain time within the critical temperature range described above. The drying step S4 may remove bubbles from the mixed liquid that is dried in the molding mold 5 through the pipetting unit 8. [

The surface treatment step (S5) treats the surface of the molding die (5) as hydrophobic prior to the mixed liquid applying step (S3). The surface treatment step (S5) can treat the surface of the molding mold (5) by hydrophobic treatment through the surface treatment unit (6) where the oxygen plasma is generated. The surface treatment step (S5) can dry the molding mold (5) through the surface treatment unit (6) at room temperature for about one day. The surface of the molding die 5 is changed from hydrophilic to hydrophobic by the surface treatment step S5 so that the mixed liquid is applied to the molding die 5 in a uniform thickness. A virtual film is formed between the mixed liquid and the molding die 5 by the hydrophobic property of the surface of the molding die 5 so that the finished salmon nucleic acid film 10 is safely separated from the molding die 5 .

The method may further include a mold preparation step (S6) of processing the molding mold (5) corresponding to the shape of the salmon nucleic acid film (10) completed before the surface treatment step (S5). The mold preparation step (S6) can process the molding die (5) having a flat surface.

At this time, the forming mold 5 may be composed of the first mold 301. 3 (a), a needle groove 311 having a narrow width along the thickness direction can be formed on the surface of the first mold 301. In this case, Thus, the microneedles 11 protrude from the salmon nucleic acid film 10 which is finally completed.

Further, the forming mold 5 may be composed of a second mold 302. 3B, a buffering groove 312 may be formed on the surface of the second mold 302 to receive a drug 40, which will be described later. In addition, the needle groove 311 may be further recessed in the buffer forming groove 312. The buffer groove 12 is convexly formed toward the skin of the human body while the outer surface of the buffer groove 12 is protruded toward the skin of the human body through the micro needle 11 ) Are projected.

Further, the forming mold 5 may be composed of a third mold 303. 3 (c), a transfer groove 313 having a narrow width along the thickness direction is formed in the surface of the third mold 303, while a transfer groove 313 is formed in the transfer groove 313, The protrusion 314 can be protruded. Thus, the drug delivery portion 13 is protruded from the salmon nucleic acid film 10, and the drug injection hole 14 is formed through the drug delivery portion 13.

The film obtaining step S7 separates the salmon nucleic acid film 10 from the molding mold 5 through the drying step S4. The salmon nucleic acid film 10 having a predetermined thickness can be obtained through the film obtaining step S7. Here, the salmon nucleic acid film 10 may have a thickness of 10 nanometers to several hundreds of micrometers. For example, the salmon nucleic acid film 100 can form a thickness of several hundred nanometers.

Hereinafter, a drug infusion apparatus using a salmon nucleic acid film according to a first embodiment of the present invention will be described. FIG. 5 is a cross-sectional view illustrating a drug injection device using a salmon nucleic acid film according to a first embodiment of the present invention.

Referring to FIGS. 1 to 4 and 5, the drug injection device using the salmon nucleic acid film according to the first embodiment of the present invention is applied to the salmon nucleic acid film 10 manufactured by the above-described manufacturing method.

The drug injection device using salmon nucleic acid film according to the first embodiment of the present invention includes a salmon nucleic acid film 10, a finishing film 30, and a drug 40.

The salmon nucleic acid film 10 is prepared by the above-described method for producing a salmon nucleic acid film, and is brought into contact with the skin of the human body. At this time, the microneedles 11 may be protruded from the salmon nucleic acid film 10 by the needle grooves 311 formed in the molding die 5. The microneedles 11 may extend from the surface of the salmon nucleic acid film 10 so as to face the skin of the human body.

Here, the microneedles 11 may have a cross-sectional shape gradually decreasing from the surface of the salmon nucleic acid film 10 to exhibit a concave cone shape. The maximum diameter of the surface side of the salmon nucleic acid film 10 in the microneedle 11 (the diameter with respect to a virtual circle in which the cross-sectional area of the micro needle 11 is in contact) is 200 to 400 micrometers, The tip diameter of the microneedle 11 may be 20 to 30 micrometers and the protrusion length of the microneedle 11 may be 200 to 300 micrometers. If the microneedle 11 is out of the defined numerical range, the shape of the microneedle 11 may collapse or the salmon nucleic acid film 10 may be bent. However, by limiting the size of the micro needle 11 in the present invention, it is possible to stabilize the projecting shape of the salmon nucleic acid film 10, to facilitate penetration of the drug 40 into the skin, It is possible to prevent the micro needle 11 from being broken when the salmon nucleic acid film 10 is separated from the molding die 5.

The finish film (30) is laminated and supported on the salmon nucleic acid film (10). Here, the termination film 30 is not limited, and the drug 40 is not deteriorated through various forms.

The drug (40) is filled between the salmon nucleic acid film (10) and the finishing film (30). The drug (40) does not decompose the salmon nucleic acid film (10). The medicament 40 may be made of any one selected from the group consisting of a therapeutic agent or a health-aid agent including hormone control, anesthesia, anti-aging, wrinkle removal, tattoo removal, tattoo formation and skin absorption. For example, the medicament 40 may comprise hyaluronic acid for anti-aging or wrinkle removal.

If the salmon nucleic acid film 10 is attached to the skin of the human body, water remaining on the surface of the salmon nucleic acid film 10 or water remaining on the skin of the human body or the skin of the salmon nucleic acid film 10 and the skin of the human body The drug 40 may be infiltrated into the skin of the human body by decomposing the salmon nucleic acid film 10 by distilled water or deionized water applied to at least one of them.

The drug infusion device using the salmon nucleic acid film according to the first embodiment of the present invention may further include a boundary film 20. [ The boundary film (20) is stacked and supported between the salmon nucleic acid film (10) and the finishing film (30). The drug (40) is filled between the salmon nucleic acid film (10) and the boundary film (20). Between the boundary film (20) and the finishing film (30), a decomposition liquid (50) is filled. The decomposition liquid 50 may be composed of distilled water or deionized water. At this time, a perforation needle (31) for perforating the boundary film (20) is protruded from the finishing film (30).

Accordingly, when the drug infusion device is attached to the skin of the human body and is pressed without applying extra distilled water or deionized water to the salmon nucleic acid film 10, the perforated needle 31 can penetrate the boundary film 20 The decomposition liquid 50 is moved toward the drug 40 and the decomposition liquid 50 decomposes the salmon nucleic acid film 10 to penetrate the skin of the human body have.

Hereinafter, a drug infusion apparatus using a salmon nucleic acid film according to a second embodiment of the present invention will be described. 6 is a cross-sectional view illustrating a drug injection device using a salmon nucleic acid film according to a second embodiment of the present invention.

Referring to FIGS. 1 to 4 and 6, the drug injection device using the salmon nucleic acid film according to the second embodiment of the present invention is applied to the salmon nucleic acid film 10 manufactured by the above-described manufacturing method.

The drug infusion device using the salmon nucleic acid film according to the second embodiment of the present invention includes a salmon nucleic acid film 10, a boundary film 20, a finishing film 30, a drug 40, ).

The salmon nucleic acid film 10 is prepared by the above-described method for producing a salmon nucleic acid film, and is brought into contact with the skin of the human body. At this time, the buffer groove 12 may be formed in the salmon nucleic acid film 10 by the buffer forming groove 312 formed in the forming mold 5. The buffer groove 12 forms a space for accommodating the drug 40. The micro needle 11 may be protruded from the buffer groove 12 by the needle groove 311. The buffer groove 12 protrudes toward the skin of the human body and the micro needle 11 can be extended in the buffer groove 12 to face the skin of the human body.

The boundary film (20) is laminated and supported on the salmon nucleic acid film (10). In this case, the boundary film 20 is not limited, and the drug 40 and the decomposition solution 50 are separated from each other through various forms, and the perforation needle 31 protruding from the finishing film 30 Lt; / RTI >

The finishing film (30) is laminated and supported on the boundary film (20). Here, the termination film 30 is not limited, and the drug 40 is not deteriorated through various forms. At this time, a perforation needle (31) for perforating the boundary film (20) is protruded from the finishing film (30).

The drug (40) is filled between the salmon nucleic acid film (10) and the boundary film (20). The drug (40) does not decompose the salmon nucleic acid film (10). The medicament 40 may be made of any one selected from the group consisting of a therapeutic agent or a health-aid agent including hormone control, anesthesia, anti-aging, wrinkle removal, tattoo removal, tattoo formation and skin absorption. For example, the medicament 40 may comprise hyaluronic acid for anti-aging or wrinkle removal.

The decomposition liquid (50) is filled between the boundary film (20) and the finishing film (30). The decomposition liquid 50 may be composed of distilled water or deionized water.

Accordingly, when the drug infusion device is attached to the skin of the human body and is pressed without applying extra distilled water or deionized water to the salmon nucleic acid film 10, the perforated needle 31 can penetrate the boundary film 20 The decomposition liquid 50 is moved toward the drug 40 and the decomposition liquid 50 decomposes the salmon nucleic acid film 10 to penetrate the skin of the human body have.

Hereinafter, a drug infusion apparatus using a salmon nucleic acid film according to a third embodiment of the present invention will be described. 7 is a cross-sectional view illustrating a drug injection device using a salmon nucleic acid film according to a third embodiment of the present invention.

Referring to FIGS. 1 to 4 and 7, the drug injection device using the salmon nucleic acid film according to the third embodiment of the present invention is applied to the salmon nucleic acid film 10 manufactured by the above-described manufacturing method.

The drug injection device using the salmon nucleic acid film according to the third embodiment of the present invention includes a salmon nucleic acid film 10, a boundary film 20, a finishing film 30, a drug 40, ).

The salmon nucleic acid film 10 is prepared by the above-described method for producing a salmon nucleic acid film, and is brought into contact with the skin of the human body. At this time, the drug delivery portion 13 may be protruded from the salmon nucleic acid film 10 by the transfer groove 313 formed in the molding die 5. In addition, the drug injection hole 14 may be formed in the drug delivery portion 13 by the injection protrusion 314. The drug delivery portion 13 extends from the salmon nucleic acid film 10 toward the skin of the human body and the drug injection hole 14 is formed by the surface tension of the drug 40, .

The boundary film (20) is laminated and supported on the salmon nucleic acid film (10). In this case, the boundary film 20 is not limited, and the drug 40 and the decomposition solution 50 are separated from each other through various forms, and the perforation needle 31 protruding from the finishing film 30 Lt; / RTI >

The finishing film (30) is laminated and supported on the boundary film (20). Here, the termination film 30 is not limited, and the drug 40 is not deteriorated through various forms. At this time, a perforation needle (31) for perforating the boundary film (20) is protruded from the finishing film (30).

The drug (40) is filled between the salmon nucleic acid film (10) and the boundary film (20). The drug (40) does not decompose the salmon nucleic acid film (10). The medicament 40 may be made of any one selected from the group consisting of a therapeutic agent or a health-aid agent including hormone control, anesthesia, anti-aging, wrinkle removal, tattoo removal, tattoo formation and skin absorption. For example, the medicament 40 may comprise hyaluronic acid for anti-aging or wrinkle removal.

The decomposition liquid (50) is filled between the boundary film (20) and the finishing film (30). The decomposition liquid 50 may be composed of distilled water or deionized water.

Accordingly, when the drug injection device is attached to the skin of the human body without applying any additional distilled water or deionized water to the salmon nucleic acid film 10, the perforation needle 31 punctures the boundary film 20 The decomposition liquid 50 is moved toward the drug 40 and the drug 40 can be penetrated into the skin of the human as the decomposition liquid 50 decomposes the salmon nucleic acid film 10 .

The drug infusion device using the salmon nucleic acid film according to the third embodiment of the present invention further includes a protective film 60 and may further include a separation layer 70.

The protective film 60 is detachably coupled to the salmon nucleic acid film 10 so that the drug infusion hole 14 is opened and closed. In addition, the separation layer 70 is fixed to the protective film 60 so as to be detachably attached to the salmon nucleic acid film 10. The separation layer (70) is not mixed with the drug (40).

The protective film 60 or the separation layer 70 further prevents leakage of the drug 40 into the drug infusion hole 14 during transportation or storage of the drug infusion device, It is possible to prevent the foreign matter from flowing into the discharge port 14.

Hereinafter, a drug infusion apparatus using a salmon nucleic acid film according to a third embodiment of the present invention will be described. FIG. 8 is a cross-sectional view illustrating a drug injection device using a salmon nucleic acid film according to a fourth embodiment of the present invention.

Referring to FIGS. 1 to 4 and 8, a drug injector using a salmon nucleic acid film according to a fourth embodiment of the present invention is characterized in that the salmon nucleic acid 1b and the drug And the salmon nucleic acid film 10 prepared by mixing all of the salmon nucleic acid films 40 are applied.

A drug injection device using a salmon nucleic acid film according to a fourth embodiment of the present invention comprises a salmon nucleic acid film 10. The salmon nucleic acid film 10 is composed of a salmon nucleic acid film 10 prepared by mixing the salmon nucleic acid 1b and the drug 40 in the aqueous solution 1b. At this time, the microneedles 11 according to the first embodiment of the present invention may protrude from the salmon nucleic acid film 10.

The drug infusion device using the salmon nucleic acid film according to the fourth embodiment of the present invention may further include a boundary film 20, a finishing film 30, and a decomposition solution 50.

The boundary film 20, the finishing film 30 and the decomposition liquid 50 according to the fourth embodiment of the present invention are the same as those of the first embodiment to the third embodiment And a description thereof will be omitted.

According to the above-described method of producing a salmon nucleic acid film and a drug injection device using a salmon nucleic acid film, by applying the salmon nucleic acid film 10 in a transdermal delivery technique that depends on drug diffusion across human skin, And the skin penetration degree of the drug 40 can be improved. It is also possible to easily form the drug delivery portion 13 in which the microneedles 11, the buffer grooves 12 and the drug infusion holes 14 penetrate through the salmon nucleic acid film 10, The thickness of the nucleic acid film 10 can be made uniform.

In addition, it is possible to prevent foreign matter from mixing with the salmon nucleic acid film 10 and to improve the degree of decomposition of the salmon nucleic acid film 10. In addition, the decomposition liquid 50 may be stably supplied to the salmon nucleic acid film 10 to stabilize the supply of the drug 40. Further, a pattern according to the dosage form of the drug 40 can be formed, and the dosage of the drug 40 can be controlled according to the pattern.

In addition, it is possible to prevent the drug 40 from leaking from the drug infusion hole 14, to prevent foreign substances from being mixed into the drug 40, and to protect the salmon nucleic acid film 10.

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed embodiments, but, on the contrary, Modify or modify the Software.

S1: mixing step S2: stirring step S3: mixing liquid application step
S4: drying step S5: surface treatment step S6: mold preparing step
S7: Film acquisition step 1: Mixing container 1a: Aqueous solution
1b: Salmon nucleic acid 2: Stirring unit 3: Magnetic
4: seal member 5: forming mold 301: first mold
302: second mold 303: third mold 311: needle groove
312: buffer forming groove 313: transfer groove 314:
6: surface treatment unit 7: drying unit 8: pipetting unit
10: Salmon nucleic acid film 11: Micro needle 12: Buffer groove
13: Drug delivery part 14: Drug injection hole 20: Boundary film
30: Finishing film 31: Perforation needle 40: Drug
50: decomposition liquid 60: protective film 70: separation layer

Claims (12)

Adding 0.5 to 5 parts by weight of salmon nucleic acid to 100 parts by weight of distilled water or deionized water in the form of powder to form a mixed solution;
Stirring the mixed liquid through the mixing step;
Applying the mixed solution to a molding mold corresponding to the shape of the finished salmon nucleic acid film;
A drying step of drying the mixed liquid applied to the molding die so that the mixed liquid applied to the molding die is converted into the salmon nucleic acid film; And
And a film obtaining step of separating the salmon nucleic acid film from the molding mold through the drying step,
The forming mold is recessed in one of the following three forms,
1) Needle groove narrowing in width along the thickness direction,
2) a buffer-forming groove for allowing the drug to be accommodated; a needle groove for narrowing the width along the thickness direction in correspondence with the micro-
3) a transmission groove having a narrow width along the thickness direction (in this case, an injection projection protrudes from the center of the transmission groove)
Wherein the salmon nucleic acid film is provided with a microneedle corresponding to the needle groove or a drug delivery portion protruding through the center of the drug injection hole corresponding to the transfer groove and the injection projection,
Wherein the microneedle or the drug delivery unit has a cross-sectional shape gradually decreasing from a surface of the salmon nucleic acid film, thereby forming a concave cone shape. The method according to claim 1,
Further comprising a surface treatment step of treating the surface of the molding die with a hydrophobic property before the step of applying the mixed solution. delete The method according to claim 1,
Wherein 1 to 100 parts by weight of the drug is further added to the mixed solution in the form of a liquid, a powder or a capsule. A salmon nucleic acid film produced according to the manufacturing method as described in claim 1 to be in contact with human skin;
A finish film laminated and supported on the salmon nucleic acid film; And
And a drug filled between the salmon nucleic acid film and the finish film. A salmon nucleic acid film produced according to the manufacturing method as described in claim 1 to be in contact with human skin;
A boundary film laminated and supported on the salmon nucleic acid film;
A finishing film laminated and supported on the boundary film, the finishing film having a perforation needle protruding from the boundary film;
A drug filled between the salmon nucleic acid film and the boundary film; And
And a decomposition liquid filled between the boundary film and the finish film, the decomposition liquid being composed of distilled water or deionized water. A drug injection device using a salmon nucleic acid film characterized by comprising a salmon nucleic acid film produced according to the production method of claim 4 so as to be in contact with the skin of a human body. 8. The method of claim 7,
A boundary film laminated and supported on the salmon nucleic acid film;
A finishing film laminated and supported on the boundary film, the finishing film having a perforation needle protruding from the boundary film; And
Further comprising a decomposition liquid filled between the boundary film and the finish film, the decomposition liquid comprising distilled water or deionized water. delete delete delete 9. The method according to any one of claims 5 to 8,
And a protective film detachably coupled to the salmon nucleic acid film. ≪ Desc / Clms Page number 19 >

Images